Delaware
|
000-54586
|
27-0801073
|
||
(State or other jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer
|
||
incorporation)
|
Identification No.)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 FR 240.13e-4(c))
|
(b)
|
Effective as of June 30, 2014 (the “Termination Date”), Kenneth A. Tassey, Jr. resigned as President and a director of Boston Therapeutics, Inc. (the “Company”). Mr. Tassey’s resignation was not the result of any disagreements with the Company regarding its operations, policies, or practices.
|
(e)
|
On June 30, 2014, the Company entered into a Separation Agreement and General Release with Mr. Tassey, pursuant to which the Company agreed to pay Mr. Tassey’s salary and to provide him with health insurance for a period of 6 months following the Termination Date. Mr. Tassey in turn granted the Company a general release and agreed to maintain the confidentiality of the Company’s confidential information and not to attempt to hire the Company’s employees for a period of 24 months following the Termination Date.
|
(d)
|
Exhibits
|
BOSTON THERAPEUTICS, INC.
|
|||
|
|
|
|
Date: July 3, 2014
|
By:
|
/s/ David Platt, Ph.D
|
|
David Platt
|
|||
Chief Executive Officer
|